Home/Filings/4/0001741533-25-000003
4//SEC Filing

Paolini John F. 4

Accession 0001741533-25-000003

CIK 0001730430other

Filed

Nov 3, 7:00 PM ET

Accepted

Nov 4, 4:36 PM ET

Size

21.7 KB

Accession

0001741533-25-000003

Insider Transaction Report

Form 4
Period: 2025-10-31
Paolini John F.
CHIEF MEDICAL OFFICER
Transactions
  • Exercise/Conversion

    Class A Ordinary Share

    2025-10-31$3.80/sh+36,542$138,86097,866 total
  • Exercise/Conversion

    Class A Ordinary Share

    2025-10-31$8.83/sh+46,000$406,180143,866 total
  • Exercise/Conversion

    Share Option

    2025-10-3136,5420 total
    Exercise: $3.80Exp: 2027-06-28Class A Ordinary Share (36,542 underlying)
  • Sale

    Class A Ordinary Share

    2025-10-31$37.14/sh82,542$3,065,61061,324 total
  • Exercise/Conversion

    Share Option

    2025-10-3146,0000 total
    Exercise: $8.83Exp: 2029-09-16Class A Ordinary Share (46,000 underlying)
Footnotes (3)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025.
  • [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.80 and $37.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F3]The option is fully vested and exercisable.

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

Entity typeother

Related Parties

1
  • filerCIK 0001741533

Filing Metadata

Form type
4
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 4:36 PM ET
Size
21.7 KB